Eric Joseph
Stock Analyst at JP Morgan
(0.65)
# 3,317
Out of 5,182 analysts
125
Total ratings
33.33%
Success rate
-14.69%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.15 | +249.21% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $33.69 | +45.44% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $24.23 | +89.85% | 4 | Oct 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $70 → $71 | $95.36 | -25.55% | 7 | Sep 25, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $85.27 | -24.94% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.46 | +102.31% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.34 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.97 | -12.17% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $68.90 | -2.76% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.18 | - | 4 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.31 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.79 | +89.99% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $9.06 | +54.53% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $24.78 | +53.35% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.49 | +412.25% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.09 | +139.77% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $12.45 | +68.67% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.25 | -24.53% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.51 | +893.38% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.84 | +111.27% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $16.93 | -35.03% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $21.57 | +363.61% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.19 | +128.31% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.87 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $52.78 | -79.16% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $27.40 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $6.32 | +1,798.73% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $8.09 | +3,608.28% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.89 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.39 | +547.48% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.32 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.50 | +1,580.00% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.53 | +268.27% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.28 | +3,848.31% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.15
Upside: +249.21%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $33.69
Upside: +45.44%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $24.23
Upside: +89.85%
Revolution Medicines
Sep 25, 2025
Maintains: Overweight
Price Target: $70 → $71
Current: $95.36
Upside: -25.55%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $85.27
Upside: -24.94%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.46
Upside: +102.31%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.34
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.97
Upside: -12.17%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $68.90
Upside: -2.76%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.31
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.79
Upside: +89.99%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $9.06
Upside: +54.53%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $24.78
Upside: +53.35%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.49
Upside: +412.25%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.09
Upside: +139.77%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $12.45
Upside: +68.67%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $13.25
Upside: -24.53%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.51
Upside: +893.38%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.84
Upside: +111.27%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $16.93
Upside: -35.03%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $21.57
Upside: +363.61%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.19
Upside: +128.31%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $5.87
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $52.78
Upside: -79.16%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $27.40
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $6.32
Upside: +1,798.73%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $8.09
Upside: +3,608.28%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $10.89
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.39
Upside: +547.48%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.32
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.50
Upside: +1,580.00%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.53
Upside: +268.27%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.28
Upside: +3,848.31%